ERIC 2022 | Current situation of CAR-T therapy for CLL
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, comments on the slower pace in the development of CAR-T therapies for chronic lymphocytic leukemia (CLL) compared to other hematological malignancies. Dr Ruella explains that whilst clinical trials have shown CAR-Ts to be effective in this setting, the complete response rate (CRR) remains lower in CLL. Together with the active development of agents like venetoclax and ibrutinib, the interest in sponsoring the development of CAR-T therapies for CLL has diminished. However, Dr Ruella believes that the situation will change since young, high-risk patients would benefit from the potential curative option CAR-Ts may represent in CLL. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
